Delstrigo

HIV, Treatment Naive, HIV + 3 more
Treatment
3 FDA approvals
20 Active Studies for Delstrigo

What is Delstrigo

LamivudineThe Generic name of this drug
Treatment SummaryTenofovir disoproxil fumarate, sold under the brand name Viread, is a medication used to treat HIV and hepatitis B. It belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (nRTIs), and is meant to be taken in combination with other medications. Tenofovir disoproxil was approved by the FDA in 2001.
Epiviris the brand name
image of different drug pills on a surface
Delstrigo Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Epivir
Lamivudine
1995
178

Approved as Treatment by the FDA

Lamivudine, otherwise called Epivir, is approved by the FDA for 3 uses which include HIV and Chronic Hepatitis B Infection .
HIV
Used to treat Human Immunodeficiency Virus Type 1 (HIV-1) Infection in combination with Abacavir
Chronic Hepatitis B Infection
HIV

Effectiveness

How Delstrigo Affects PatientsTenofovir is used to treat HIV-1 and Hepatitis B infections by preventing the virus from making copies of itself. Laboratory tests have shown that it is effective against HIV-1 at concentrations between 0.04 μM to 8.5 μM. Tenofovir has been found to work well in combination with other drugs used to treat HIV-1, such as nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors, as well as protease inhibitors. Clinical studies have also confirmed that it can effectively fight HIV-1 in cell cultures.
How Delstrigo works in the bodyTenofovir is an antiretroviral medicine used to reduce the amount of HIV in the body. It works by blocking a special enzyme that HIV needs to reproduce. When this enzyme is blocked, the virus can't make as many copies of itself. Tenofovir is absorbed and converted to its active form which is a type of chemical called a nucleotide analog. This chemical then binds to the HIV enzyme and stops it from working. It also prevents the virus from making DNA. In some cases, HIV can become resistant to tenofovir, meaning that it is not as effective at stopping the virus from reproducing

When to interrupt dosage

The suggested dosage of Delstrigo is based on the identified affliction, including Anti-Retroviral Agents, High Risk Patients and Chronic Hepatitis B. The measure of dosage fluctuates, depending on the procedure of delivery (e.g. Tablet or Tablet, film coated) provided in the table below.
Condition
Dosage
Administration
HIV
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral
Treatment Naive
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral
HIV
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral
Anti-Retroviral Agents
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral
Chronic Hepatitis B Infection
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral
treatment failure
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral

Warnings

There are 20 known major drug interactions with Delstrigo.
Common Delstrigo Drug Interactions
Drug Name
Risk Level
Description
Aclidinium
Minor
Lamivudine may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine
Minor
Lamivudine may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Lamivudine may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Allylestrenol
Minor
Lamivudine may decrease the excretion rate of Allylestrenol which could result in a higher serum level.
Almasilate
Minor
Lamivudine may decrease the excretion rate of Almasilate which could result in a higher serum level.
Delstrigo Toxicity & Overdose RiskWhen it comes to breastfeeding, the Centers for Disease Control and Prevention recommend that mothers with HIV-1 not breastfeed their infants to prevent transmission. Mothers should not breastfeed if they are taking tenofovir disoproxil. There have been no studies done on pregnant women taking tenofovir disoproxil, but studies done on rats and rabbits showed no signs of harm to the fetus at doses up to 14 and 19 times the recommended human dose. To monitor the effects of this drug on pregnant women, a registry has been created for healthcare providers to register patients. Tenofov

Delstrigo Novel Uses: Which Conditions Have a Clinical Trial Featuring Delstrigo?

Currently, 46 active clinical trials are assessing the potential of Delstrigo to replace a current antiretroviral treatment regimen for certain virologically suppressed (HIV1 RNA <50 copies/mL) adult patients on a stable regimen at the start of therapy, as well as in treating Chronic Hepatitis B and HIV (Human Immunodeficiency Virus).
Condition
Clinical Trials
Trial Phases
HIV
155 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1
HIV
40 Actively Recruiting
Phase 2, Phase 3, Phase 1, Early Phase 1, Not Applicable, Phase 4
Chronic Hepatitis B Infection
8 Actively Recruiting
Phase 3, Phase 2, Phase 1
Treatment Naive
0 Actively Recruiting
treatment failure
0 Actively Recruiting
Anti-Retroviral Agents
0 Actively Recruiting

Delstrigo Reviews: What are patients saying about Delstrigo?

2Patient Review
6/25/2021
Delstrigo for HIV
I gained weight when I switched to delstrigo, and my hiv 1rna levels increased.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about delstrigo

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Delstrigo?

"The most common side effects of Delstrigo include abnormal dreams, difficulty sleeping, nightmares, depression, headaches, dizziness, drowsiness, coughing, an irritated or runny nose, nausea, diarrhea, abdominal pain, vomiting, hair loss, rashes, muscle disorders, fatigue, and fever."

Answered by AI

What does Delstrigo do?

"The DELSTRIGO prescription medication is used to treat HIV-1 infection in adults who have not received HIV-1 medicines in the past, or to replace their current HIV-1 medicines. This decision is made by the patient's healthcare provider after determining that the patient meets certain requirements."

Answered by AI

Who manufactures Delstrigo?

"The European Commission red lighted Merck's DELSTRIGO (doravirine / lamivudine / tenofovir disoproxil fumarate), a once-daily fixed-dose combination tablet as a complete regimen and PIFELTRO (doravirine), an NNRTI, both for the treatment of HIV-1 in [the European Union]."

Answered by AI

How good is Delstrigo?

"In a study of 728 adults, 84% of those treated with Delstrigo had undetectable HIV levels in their blood (fewer than 40 copies/ml) after 48 weeks, compared to 80% of those given a combination of efavirenz, emtricitabine, and tenofovir disoproxil."

Answered by AI

Clinical Trials for Delstrigo

Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL
The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.
Phase < 1
Waitlist Available
University of Alabama at Birmingham
Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA
This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.
Waitlist Available
Has No Placebo
Los Angeles General Medical CenterHayoun Lee, PhD
Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC
This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.
Phase 1
Recruiting
University of North CarolinaCynthia L. Gay, MD
Have you considered Delstrigo clinical trials? We made a collection of clinical trials featuring Delstrigo, we think they might fit your search criteria.Go to Trials
Have you considered Delstrigo clinical trials? We made a collection of clinical trials featuring Delstrigo, we think they might fit your search criteria.Go to Trials
Image of UCSF in San Francisco, United States.

N-803 for HIV

18 - 70
All Sexes
San Francisco, CA
Even though HIV medicine stops the virus from making more copies of itself, the virus remains in the body by hiding inside of immune cells. This hidden virus is referred to as the "latent reservoir." Researchers on this team are studying whether stimulating the immune system can change the nature of the latent reservoir and if this could help people control HIV without the need to take regular HIV medicine. This study is testing a drug called N-803. N-803 is also known as Interleukin-15 or "IL-15", a powerful and long lasting protein that can affect the immune system by stimulating immune cells such as CD8+ T cells and natural killer (NK) cells. CD8+ T cells and NK cells are both crucial for eliminating infected cells. The drug is FDA-approved for the treatment of bladder cancer, but in this study the drug is being used experimentally for HIV.
Phase 2
Waitlist Available
UCSF
Image of Alabama CRS (Site ID: 31788) in Birmingham, United States.

Dasatinib + Quercetin for HIV

18+
All Sexes
Birmingham, AL
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Phase 2
Waitlist Available
Alabama CRS (Site ID: 31788) (+26 Sites)
Image of Yale University in New Haven, United States.

DynamiCare + Patient Navigation for Stimulant Use Disorder

18+
All Sexes
New Haven, CT
Justice-involved individuals face disproportionately high rates of stimulant use disorder and HIV, along with disrupted access to HIV treatment and prevention services like ART and PrEP. Contingency management (CM) is the most effective intervention for stimulant use, but its use in justice-involved populations has been limited by logistical and structural barriers. DynamiCare is an FDA-approved mobile app that delivers behavioral CM and has shown promise in reducing stimulant use, but its impact on HIV-related outcomes remains unknown. The RESTORE study (Recovery and Engagement for Stimulant Users on Re-entry) will evaluate whether combining DynamiCare with patient navigation (DynamiCare-plus) improves PrEP/ART initiation and reduces stimulant use among individuals recently released from justice settings. The R61 phase will assess feasibility, acceptability, and preliminary effectiveness among 40 participants. If milestones are met, the R33 phase will scale to a randomized controlled trial with 252 participants to assess effectiveness, implementation, and cost. This scalable, mobile approach has the potential to address a critical gap in care for a highly vulnerable population.
Waitlist Available
Has No Placebo
Yale University (+1 Sites)Ank Nijhawan, MD
Have you considered Delstrigo clinical trials? We made a collection of clinical trials featuring Delstrigo, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security